Background. Isoflurane preconditioning (IPC) induces cerebral ischaemic tolerance, but the mechanism remains poorly understood. The aim of this study was to determine changes in mitochondrial function in the brain after IPC, and whether the cannabinoid receptor 1 (CB1R) could be involved in the mechanism of mitochondrial protection mediated by IPC. Methods. Adult male Sprague-Dawley rats were pretreated with isoflurane 2% for 1 h day
ischaemia. 3 4 However, the exact molecular and subcellular mechanisms underlying the neuroprotective actions of IPC are not yet clarified.
Mitochondria play a crucial role in generation of reactive oxygen species, iron homeostasis, and apoptotic signalling. 5 Mitochondrial dysfunction exacerbates I/R injury with activation of mitochondrial apoptotic cascades; [6] [7] [8] therefore, mitochondria could be a mechanistic target for the neuroprotective effect of preconditioning after brain ischaemic damage. [9] [10] [11] [12] However, the mechanism of regulation of mitochondrial function by preconditioning requires further exploration. Cannabinoid receptor 1 (CB1R) is a G-protein-coupled receptor, located in the neuronal plasma membrane, which modulates neuronal activity, synaptic plasticity, and cell metabolism. 13 Accumulating evidence has demonstrated a substantial role for CB1R in neuroprotection 14 15 and in the brain ischaemic tolerance induced by ischaemic preconditioning and electro-acupuncture. 16 17 Inhibition of CB1R using antagonists or a knockout strategy blocked neuroprotection both in vivo and in vitro. [18] [19] [20] Recent investigations showed that CB1R was also expressed in neuronal mitochondrial membranes (mtCB1R), regulating mitochondrial respiration, energy metabolism, and other functions. 21 22 However, the involvement of mtCB1R in the neuroprotection induced by IPC is still unknown.
In the present study, we used a transient focal cerebral I/R model in rats and Ca 2þ -induced injury in purified intact mitochondria to investigate the role of mtCB1R in the neuroprotection induced by IPC both in vitro and in vivo.
Methods

Animals
All animal-related procedures were approved by the Ethics Committee for Animal Experimentation of the Fourth Military Medical University (Xi'an, China), in accordance with the US National Institutes of Health Guide for the Care and Use of Laboratory Animals and relevant aspects of the ARRIVE guidelines.
Male Sprague-Dawley rats (8-10 weeks old), weighing 270-320 g, were used. The animals were housed with a 12 h-12 h light-dark cycle, at [20] [21] [22] [23] [24] [25] C, and 60% humidity. Unrestricted water and food were available.
Experimental protocols
Experiment 1
The long-term neuroprotective effect of IPC was determined. Rats (n¼8 per group) were divided into three groups as follows:
sham, middle cerebral artery occlusion (MCAO), and isoflurane preconditioning (ISO group). Seven days after reperfusion, neurological outcome and infarct volume were determined. Full details are provided in the Supplementary file S1.
Experiment 2
Cannabinoid receptor 1 expression after IPC was examined. Rats were allocated to two groups without MCAO: oxygen control or isoflurane preconditioning (IPC). Cannabinoid receptor 1 protein expression was evaluated by western blot in control rats and at different time points (2, 6, 12, 24 , and 48 h, n¼6 at each time point) after IPC. Cannabinoid receptor 1 immunofluorescence staining was also undertaken in both control and IPC groups at 6 h (n¼3). In addition, at the same time point as the last IPC, CB1R expression in plasma membrane and mitochondria was assessed in isolated mitochondria by western blot (n¼6) and immunogold electron microscopy (n¼3).
Experiment 3
To investigate the role of CB1R in IPC-mediated neuroprotection and amelioration of mitochondrial dysfunction, the CB1R agonist HU-210 was pre-administered based on a previous study.
21
Twenty-four rats were divided into three groups (sham, MCAOþvehicle, and MCAOþHU-210), and neurological behaviour, infarct volume, and apoptosis [terminal deoxynucleotidyl transferase-mediated 2 0 -deoxyuridine 5 0 -triphosphate nick-end labelling (TUNEL) staining] were measured. Additionally, two CB1R antagonists, AM251 and SR141716, were administrated as described previously. 16 23 Forty-eight rats were divided into the following six groups: sham, MCAO, ISO (IPCþMCAO), ISOþAM251 (IPCþMCAOþAM251), ISOþvehicle (IPCþMCAOþve-hicle), and ISOþSR141716 (IPCþMCAOþSR141716). Neurological outcome, cerebral infarct volume, and apoptosis level (TUNEL staining, prosurvival protein expression, and cleaved caspase-3 concentrations) were evaluated 72 h after reperfusion. The activity of mitochondrial respiratory chain complexes was also measured 4 and 24 h after reperfusion.
Experiment 4
Citrate synthase, mitochondria membrane potential (MMP), mitochondrial permeability transition pore (mPTP) opening, and total radical production were measured in isolated mitochondria. Intact brain mitochondria were divided into the following seven groups: sham; control, where 200 lM CaCl 2 was added to induce mitochondrial dysfunction; ISO, where mitochondria were pre-incubated with isoflurane (0.5 mM) for 15 min, and then the suspension was diluted in isolation buffer and centrifuged at 8000g for 10 min; ISOþAM251 
Determination of activity of respiratory chain complexes
Evaluation of all respiratory chain enzyme activities was undertaken spectrophotometrically at 30 C according to methods reported previously. 24 In brief, NADH-ubiquinone oxidoreductase (complex I) activity was measured as the rate of NADH-dependent ferricyanide reduction. Succinate-2,6-dichloroindophenol (DCIP)-oxidoreductase (complex II) was measured as the reduction of 2,6-DCIP. Coenzyme Q-cytochrome c reductase (complex III)
Editor's key points
• Preconditioning with isoflurane (IPC) protects against ischaemia-reperfusion cerebral damage.
• The cannabinoid receptor CB1R modulates neuroprotection and may have a role in isoflurane-mediated effects through maintenance of mitochondrial function.
• Rats were subjected to middle cerebral artery occlusion plus IPC with and without CB1R agonist or antagonists.
• Cannabinoid receptor 1 agonists mimicked the protective effects of IPC, whereas antagonists reduced the protection.
• Neuroprotection by IPC involves the CB1R. activity was measured as cytochrome c reduction from succinate, and cytochrome c oxidase and complex IV was measured using the oxidation of previously reduced cytochrome c. Mitochondrial respiratory chain complex activities were normalized and expressed as the percentage of activity seen in the sham group.
Mitochondrial isolation
Rats were killed with an overdose of chloral hydrate and brain tissues dissected as described previously. 25 The penumbra was dissected and used for mitochondrial isolation using a proteome mitochondria isolation kit (89874; Pierce Biotechnology, Winnebago, IL, USA) according to the manufacturer's instructions. Tissue was collected and pooled, minced, and homogenized in isolation buffer (250 mM sucrose, 1 mM EGTA, 20 mM HEPES, pH 7.5). The homogenates were centrifuged to remove the nuclear fraction and intact cells, then the supernatant was centrifuged at 4000g to obtain a crude mitochondrial function. This pellet was subjected to density gradient centrifugation in Percoll, and the purified mitochondria were washed (three times) before experimentation. The integrity of the isolated mitochondria was determined by analysis of cytochrome c oxidase activity using enzyme immunoassay (Sigma-Aldrich, St Louis, MO, USA), and purified mitochondria were also examined by electron microscopy. 26 27 Mitochondrial protein concentrations were measured using the Bradford assay (Beyotime, Nantong, China). Isolated mitochondria were diluted with a swelling buffer (KCl, 120 mM; Tris-HCl, 10 mM; MOPS, 20 mM; KH 2 PO 4 , 5 mM, pH 7.4) to a final concentration of 0.5 mg protein ml À1 , and all mitochondria were used within 3 h.
Induction of mitochondrial dysfunction with Ca 21
Intact mitochondria were exposed to a high concentration of CaCl 2 (200 lM) to mimic Ca 2þ overload and induce damage, which is thought to be a crucial inducer of cerebral I/R injury. 28 
Measurement of mitochondrial function
Citrate synthase was measured in purified mitochondria using a commercial kit, according to the manufacturer's instructions (Sigma, St Louis, MO, USA). 29 30 This was confirmed using the reduction of 5,5 0 -dithiobis(2-nitrobenzoic acid) at 412 nm, coupled to the reduction of coenzyme A by the citrate synthase reaction in the presence of oxaloacetate. Mitochondria membrane potential was measured using the fluorescent probe JC-1 (5,5,6,6-tetrachloro-1,1,3,3-tetraethylbenzimidazolcarbocyanine iodide) using a commercially available kit (Sigma, USA), 31 with valinomycin as a negative control. The results were corrected for mitochondrial viability (as cytochrome c oxidase activity) and expressed as a percentage. Mitochondrial permeability transition pore opening was determined as described previously, 11 32 and total radical production was analysed using a commercially available kit (Beyotime, Nantong, China).
Statistical analysis SPSS 16.0 for Windows (SPSS Inc., Chicago, IL, USA) was used to conduct the statistical analyses. Data are shown as individual raw data points with the median and interquartile range and were analysed using the Kruskal-Wallis test followed by the Mann-Whitney U-test and Bonferroni post hoc correction. A value of P<0.05 was considered to be statistically significant.
Details of the IPC and focal cerebral I/R regime, neurological deficit and infarct volume scoring, TUNEL staining, western blotting, electron microscopy, and immunofluorescence staining are provided in the Supplementary file S1.
Results
Physiological parameters after preconditioning and various intervals of I/R are summarized in Supplementary Table S1 . There were no statistically significant differences in pH, temperature, or partial pressures of carbon dioxide between the groups.
Isoflurane preconditioning before MCAO improved neurological deficit scores compared with MCAO alone (Supplementary  Fig. S1A ; P¼0.019). Consistent with the improved neurological outcome, infarct volumes were also smaller 7 days after reperfusion (Supplementary Fig. S1B ; P¼0.014), but regional cerebral blood flow was not affected by preconditioning ( Supplementary  Fig. S1D ).
As shown in Fig. 1A , CB1R expression was increased in the IPC group only at 6 h after the last preconditioning, compared with the oxygen control group (P¼0.0069), mainly co-localized with neurones (Fig. 1B) . Expression of CB1R in the cell membrane ( Fig. 1C) and mitochondria ( Fig. 1D ) was also significantly increased at 6 h after preconditioning (P¼0.022 and P¼0.031, respectively). Immunoreactive staining of CB1R by immunogold electron microscopy in the right hemisphere area showed that intracellular CB1R was localized on the mitochondrial membrane, and the increased density of staining mtCB1R was seen in the IPC group, but not the control group (Fig. 1E) .
Treatment of MCAO animals with the CB1R agonist HU-210 resulted in improved neurological defecit scores compared with the MCAO alone group (P¼0.01; Fig. 2A ), associated with reduced infarct volume at 3 days after reperfusion (P¼0.015; Fig. 2B ). The number of TUNEL-positive cells was reduced and the number of viable cells increased in the HU-210 group compared with the MCAO group (P¼0.032 and P¼0.036, respectively; Fig. 2D-F) .
There was no IPC-mediated improvement in neurological deficit scores after MCOA in rats also given the CB1R antagonist AM251 or SR141716A at 72 h after reperfusion (P¼0.032 and P¼0.017, respectively; Fig. 3A) . The brain infarct volume was also increased (P¼0.026 and P¼0.044, respectively; Fig. 3B ). The number of TUNEL-positive cells in rats undergoing preconditioning plus MCAO was significantly reduced in comparison to MCAO without preconditioning (P¼0.007; Fig. 3D ). In rats adminstered CB1R antagonists, however, the number of TUNELpositive cells was increased and the number of viable neurones decreased ( Fig. 3E and F) .
Expression of Bcl-2 and Bcl-X L was lower at 72 h after MCOA compared with sham and was increased in rats receiving IPC plus MCAO compared with MCOA alone (P¼0.004 and P¼0.002, respectively; Fig. 4A and B) . Administration of AM251 or SR141716A abrogated the IPC-mediated increase in expression of Bcl-2 and Bcl-X L (all P<0.001; Fig. 4A and B) . Expression of cleaved caspase-3 was markedly higher in the MCAO group than in sham-treated animals and was decreased by preconditioning, and treatment with CB1R antagonists limited the reduction in caspase-3 cleavage (P¼0.029 and P¼0.008; Fig. 4C) .
At 4 and 24 h after MCAO, the activities of complexes I, III, and IV were reduced in the MCAO group compared with the sham group and increased in rats given MCAO plus IPC (Fig. 5) . The effects of IPC on mitochondrial complexes I, III, and IV were abrogated by the CB1R antagonists at both time points (all P<0.05; Fig. 5 ). There was an MCAO-induced decrease in complex II activity at 24 h but not at 4 h ( Fig. 5B and F) , and there were no other significant differences in complex II activities between groups. Isolated mitochondria were found to be round or oval, with numerous transverse cristae with parallel alignment, and mitochondrial integrity was 95% as identified by cytochrome c oxidase activity ( Fig. 6A and B) . Citrate synthase activity in mitochondrial suspensions pretreated with isoflurane or the CB1R agonist (HU-210) was increased compared with the Ca 2þ -only-treated control group (P¼0.0217 and P¼0.006, respectively), and both CB1R antagonists limited the isoflurane-induced increase in citrate synthase (P¼0.023 and P¼0.014, respectively; Fig. 6C ).
Isoflurane or HU-210 treatment significantly increased MMP compared with that seen in control mitochondria treated only with Ca 2þ (P¼0.016 and P¼0.011, respectively), and the CB1R antagonists abrogated the effect of isoflurane on MMP (P¼0.020 and P¼0.037, respectively; Fig. 6D ). Mitochondrial pore opening was reduced in isoflurane-and HU-210-treated mitochondria compared with the Ca 2þ -only control group (P¼0.013 and P¼0.024, respectively; Fig. 6E ), and again, the CB1R antagonists significantly attenuated the effect of isoflurane (P¼0.034 and P¼0.012, respectively; Fig. 6E ). The increased mitochondrial total radical production induced by Ca 2þ in the control group was attenuated by isoflurane or HU-210 (P¼0.023 and P¼0.015, respectively; Fig. 6F) , and AM251 or SR141716A both abrogated this effect (P¼0.014 and P¼0.021, respectively; Fig. 6F ). There was no effect of vehicle treatment on any measure.
Discussion
Using a transient focal cerebral I/R in vivo model and an in vitro Ca 2þ -induced injury model, we found that CB1R activation induced by IPC was involved in the improvement of mitochondrial function after brain ischaemia. Preconditioning with isoflurane or administration of the CB1R agonist HU-210 reduced infarct volume, improved neurological function, and attenuated cellular apoptosis after brain ischaemia. Isoflurane also ameliorated mitochondrial dysfunction, as indicated by preserved activity of respiratory chain complexes, increased citrate synthase activity, improved membrane potential and mPTP opening, and reduced mitochondrial total free radical generation. These benefits of isoflurane were attenuated by CB1R antagonists, suggesting a role for CB1R in the mechanism of IPC-induced neuroprotection against cerebral I/R injury. Accumulating evidence shows that regulating mitochondrial function is protective. 10 12 However, in the brain, the mechanism underlying the effect of IPC on mitochondrial function remains unclear. In mitochondria, two sites of electron transport chain are involved in electron entry; the primary one is complex I and the minor one complex II. Electrons are offered to either complex and subsequently transferred to complex III, then to complex IV. The electrochemical potential across the mitochondrial membrane is crucial for ATP production. During cerebral ischaemia, mitochondrial membrane destabilization disturbs the proton gradient and results in the opening of the mPTP, releasing mitochondrial components to initiate the apoptotic cascade. 33 34 The opening of the mPTP in the inner mitochondrial membrane subsequently results in the overproduction of radicals. 7 24 35 Therefore, in the present study, we first measured the activities of complexes I-IV of the mitochondrial electron transport chain and found that IPC induced significant increments in the activities of complexes I, III, and IV, but had little effect on complex II, at 4 and 24 h after reperfusion. These findings are consistent with previous studies from our laboratory and others. 20 To clarify the protective effect of IPC against mitochondrial injury, we used a Ca 2þ -induced injury model in isolated intact mitochondria and found that IPC increased citrate synthase activity, improved MMP depolarization, reduced mPTP opening, and decreased total radical generation, again consistent with other studies using different preconditioning stimuli. 20 36 During the early phase of ischaemia, increased mPTP opening, calcium accumulation, and decreased glucose utilization lead to neuronal cell death. 28 37 The damaged cells activate the anti-apoptotic Bcl-2 family proteins, including Bcl-2 and Bcl-X L . This maintains the permeability of the outer membrane of the mitochondria, preventing initiation of the apoptotic cascade. We found that IPC upregulated the expression of Bcl-2 and Bcl-X L and reduced cleaved caspase-3 protein expression and the number of TUNEL positive cells, indicating reduced apoptosis. These observations suggest that IPC ameliorated mitochondrial function, resulting in anti-apoptotic signalling and inducing cerebral ischaemic tolerance.
There is evidence to suggest that increased CB1R expression occurs in response to an acute ischaemic insult. In both the peripheral and the central nervous system, CB1R upregulation has been reported to regulate mitochondrial biogenesis. 38 39 We found that the CB1R agonist HU-210 elicited a neuroprotective effect via maintenance of mitochondrial function, whereas the CB1R antagonists AM251 and SR141716A counteracted the IPC-mediated improvement in mitochondrial function. These results indicate that IPC-mediated amelioration of mitochondrial function is dependent on CB1R activation, consistent with previous studies showing that CB1R is important for cerebral ischaemic tolerance induced by preconditioning agents 40 41 via preservation of mitochondrial function. 42 It has been reported that in addition to localization in the plasma membrane, CB1R is also expressed in neuronal mitochondrial membranes, with a role in regulation of mitochondrial respiration and energy metabolism in physiological conditions. 21 It has also been reported that mitochondrial CB1R
is involved in the regulation of mitochondrial function and the protective effect induced by the CB1R agonist arachidonyl-2-chloroethylamide in neurones. In the present study, we found that CB1R protein expression was decreased in the plasma membrane after MCAO, and upregulated after IPC, which could potentially be translocated from the cell membrane as indicated in other studies. 20 A recent investigation by Marsicano and colleagues 14 showed that activation of intramitochondrial G ai by mtCB1R triggered inhibition of soluble adenylyl cyclase activity, resulting in a reduction in cAMP concentrations and a decrease in intramitochondrial protein kinase A-dependent phosphorylation of oxidative phosphorylation (OXPHOS) proteins. This cascade of signals induced a decrease in brain mitochondrial activity and was required for the acute effects of exogenous cannabinoids on mitochondrial mobility and acute cannabinoidinduced memory impairment. 22 This provides a plausible explanation for how the mtCB1R could regulate mitochondrial function after IPC. Additionally, signal transduction components, such as glycogen synthase kinase-3b, signal transducer and activator of transcription 3, and protein kinase C-a, may play a role. [43] [44] [45] These signalling cascades represent the downstream signalling pathways of CB1R and contribute to multiple preconditioning paradigms and also the potential underlying mechanism, in line with the role of CB1R in modulating IPCmediated mitochondrial function. Some limitations of this study should be noted. First, we did not use mtCB1R selective knockout mice or CB1R knockout mice to confirm our findings. In addition, inhibitors of clathrinmediated endocytosis or agents that perturb clathrin-mediated internalization could be used in further experiments to evaluate whether the translocation of the CB1R from the plasma membrane to the mitochondrial membrane induced by IPC contributes to the findings reported here. 46 
Conclusion
In summary, this study demonstrated that the CB1R, especially the mtCB1R, is involved in IPC-induced cerebral ischaemic tolerance by improving mitochondrial function after cerebral I/R. These findings may reveal a new mechanism of IPC-induced neuroprotection.
